Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

This publication has 34 references indexed in Scilit:

• Adjuvant treatment of GIST: patient selection and treatment strategies
  Nature Reviews Clinical Oncology, 2012
• One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor
  JAMA, 2012
• Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing
  PLOS ONE, 2011
• Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
  Published by Elsevier ,2009
• KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
  Proceedings of the National Academy of Sciences, 2009
• Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
  Journal of Clinical Oncology, 2008
• KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
  European Journal Of Cancer, 2006
• Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
  The Lancet, 2004
• Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
  New England Journal of Medicine, 2002
• Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
  Science, 1998